Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Segment Highlights
MDT logo

Medtronic Drives 4% Organic Growth with Diabetes Surge to $2B

MDT10-QFiling Date: 2/25/2025
Medtronic plc
Description

What this story covers

Medtronic's Q3 FY2025 10-Q shows $8.3B quarterly sales up 3% organically, led by 8% Diabetes growth to $694M and Cardiovascular at 4%. Innovations like MiniMed 780G and Evolut FX+ fuel expansion. Strong $4.5B operating cash supports dividends and repurchases amid currency risks and litigation. Margins hit 20%, positioning for sustainable profitability.

Story snapshot

CompanyMedtronic plc
TickerMDT
VariantStandard detailed
Duration15:03
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001613103-25-000022

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in